Cortexyme (CRTX) Competitors

Omnicell (NASDAQ:OMCL) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Is OMCL or CRTX more profitable?

Omnicell has a net margin of 2.01% compared to Cortexyme's net margin of 0.00%. Omnicell's return on equity of 4.27% beat Cortexyme's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	2.01%	4.27%	2.44%
Cortexyme	N/A	-70.96%	-63.53%

Which has more volatility & risk, OMCL or CRTX?

Omnicell has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.

Which has higher valuation and earnings, OMCL or CRTX?

Omnicell has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.11B	1.39	$12.53M	$0.50	67.24
Cortexyme	N/A	N/A	-$89.94M	-$2.97	-0.55

Do analysts recommend OMCL or CRTX?

Omnicell currently has a consensus target price of $46.71, suggesting a potential upside of 38.95%. Given Omnicell's stronger consensus rating and higher possible upside, equities research analysts plainly believe Omnicell is more favorable than Cortexyme.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cortexyme	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do institutionals & insiders have more ownership in OMCL or CRTX?

97.7% of Omnicell shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 2.5% of Omnicell shares are held by insiders. Comparatively, 27.9% of Cortexyme shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the media prefer OMCL or CRTX?

In the previous week, Omnicell had 3 more articles in the media than Cortexyme. MarketBeat recorded 4 mentions for Omnicell and 1 mentions for Cortexyme. Omnicell's average media sentiment score of 1.71 beat Cortexyme's score of 0.59 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cortexyme	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Omnicell beats Cortexyme on 13 of the 15 factors compared between the two stocks.